Literature DB >> 21265544

Crystal structure of β-hexosaminidase B in complex with pyrimethamine, a potential pharmacological chaperone.

Katherine S Bateman1, Maia M Cherney, Don J Mahuran, Michael Tropak, Michael N G James.   

Abstract

β-Hexosaminidases (β-hex) are a group of glycosyl hydrolase isozymes that break down neutral and sialylated glycosphingolipids in the lysosomes, thereby preventing their buildup in neuronal cells. Some mutants of β-hex have decreased folding stability that results in adult-onset forms of lysosomal storage diseases. However, prevention of the harmful accumulation of glycolipids only requires 10% of wild-type activity. Pyrimethamine (PYR) is a potential pharmacological chaperone that works by stabilizing these mutant enzymes sufficiently to allow more β-hex to arrive in the lysosome, where it can carry out its function. An X-ray structure of the complex between human β-hexosaminidase B (HexB) and PYR has been determined to 2.8 Å. PYR binds to the active site of HexB where several favorable van der Waals contacts and hydrogen bonds are introduced. Small adjustments of the enzyme structure are required to accommodate the ligand, and details of the inhibition and stabilization properties of PYR are discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21265544      PMCID: PMC3201983          DOI: 10.1021/jm101443u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  32 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).

Authors:  Joe T R Clarke; Don J Mahuran; Swati Sathe; Edwin H Kolodny; Brigitte A Rigat; Julian A Raiman; Michael B Tropak
Journal:  Mol Genet Metab       Date:  2010-09-17       Impact factor: 4.797

3.  Complete analysis of the glycosylation and disulfide bond pattern of human beta-hexosaminidase B by MALDI-MS.

Authors:  C G Schuette; J Weisgerber; K Sandhoff
Journal:  Glycobiology       Date:  2001-07       Impact factor: 4.313

4.  A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates.

Authors:  Michael B Tropak; Scott W Bukovac; Brigitte A Rigat; Sayuri Yonekawa; Warren Wakarchuk; Don J Mahuran
Journal:  Glycobiology       Date:  2009-11-16       Impact factor: 4.313

5.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.

Authors:  S Ohkuma; B Poole
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

6.  An automated system to mount cryo-cooled protein crystals on a synchrotron beam line, using compact sample cassettes and a small-scale robot.

Authors:  Aina E Cohen; Paul J Ellis; Mitchell D Miller; Ashley M Deacon; R Paul Phizackerley
Journal:  J Appl Crystallogr       Date:  2002-12       Impact factor: 3.304

Review 7.  Biochemical consequences of mutations causing the GM2 gangliosidoses.

Authors:  D J Mahuran
Journal:  Biochim Biophys Acta       Date:  1999-10-08

8.  The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease.

Authors:  Timm Maier; Norbert Strater; Christina G Schuette; Ralf Klingenstein; Konrad Sandhoff; Wolfram Saenger
Journal:  J Mol Biol       Date:  2003-05-02       Impact factor: 5.469

9.  High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.

Authors:  Michael B Tropak; Jan E Blanchard; Stephen G Withers; Eric D Brown; Don Mahuran
Journal:  Chem Biol       Date:  2007-02

10.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24
View more
  15 in total

Review 1.  Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on β-hexosaminidase activity in Sandhoff fibroblasts.

Authors:  Elena Chiricozzi; Natalia Niemir; Massimo Aureli; Alessandro Magini; Nicoletta Loberto; Alessandro Prinetti; Rosaria Bassi; Alice Polchi; Carla Emiliani; Catherine Caillaud; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-12-20       Impact factor: 5.590

2.  Rare Diseases in Glycosphingolipid Metabolism.

Authors:  Hongwen Zhou; Zhoulu Wu; Yiwen Wang; Qinyi Wu; Moran Hu; Shuai Ma; Min Zhou; Yan Sun; Baowen Yu; Jingya Ye; Wanzi Jiang; Zhenzhen Fu; Yingyun Gong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease.

Authors:  Manuel González-Cuesta; Irene Herrera-González; M Isabel García-Moreno; Roger A Ashmus; David J Vocadlo; José M García Fernández; Eiji Nanba; Katsumi Higaki; Carmen Ortiz Mellet
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

4.  Gangliosides and Cell Surface Ganglioside Metabolic Enzymes in the Nervous System.

Authors:  Massimo Aureli; Laura Mauri; Emma Veronica Carsana; Dorina Dobi; Silvia Breviario; Giulia Lunghi; Sandro Sonnino
Journal:  Adv Neurobiol       Date:  2023

Review 5.  The glycosphingolipid hydrolases in the central nervous system.

Authors:  Massimo Aureli; Maura Samarani; Nicoletta Loberto; Rosaria Bassi; Valentina Murdica; Simona Prioni; Alessandro Prinetti; Sandro Sonnino
Journal:  Mol Neurobiol       Date:  2013-11-27       Impact factor: 5.590

6.  Computational study of β-N-acetylhexosaminidase from Talaromyces flavus, a glycosidase with high substrate flexibility.

Authors:  Natallia Kulik; Kristýna Slámová; Rüdiger Ettrich; Vladimír Křen
Journal:  BMC Bioinformatics       Date:  2015-01-28       Impact factor: 3.169

Review 7.  Ganglioside biochemistry.

Authors:  Thomas Kolter
Journal:  ISRN Biochem       Date:  2012-12-19

Review 8.  From structural biology to designing therapy for inborn errors of metabolism.

Authors:  Wyatt W Yue
Journal:  J Inherit Metab Dis       Date:  2016-05-30       Impact factor: 4.982

9.  Evidence that small molecule enhancement of β-hexosaminidase activity corrects the behavioral phenotype in Dutch APP(E693Q) mice through reduction of ganglioside-bound Aβ.

Authors:  E M Knight; H N Williams; A C Stevens; S H Kim; J C Kottwitz; A D Morant; J W Steele; W L Klein; K Yanagisawa; R E Boyd; D J Lockhart; E R Sjoberg; M E Ehrlich; B A Wustman; S Gandy
Journal:  Mol Psychiatry       Date:  2014-10-28       Impact factor: 15.992

Review 10.  Emerging novel concept of chaperone therapies for protein misfolding diseases.

Authors:  Yoshiyuki Suzuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2014       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.